-
Mashup Score: 5The top 100 venture investors in biotech: Who’s in, what’s out - Endpoints Webinars - 9 month(s) ago
Endpoints News’ John Carroll and DealForma’s Chris Dokomajilar are back with our latest ranking of the top 100 VCs looking to make their mark in the biotech world. And we’re highlighting the occasion with a special webinar that will focus in on the field, which has been struggling with an
Source: webinars.endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4The top 100 venture investors in biotech: Who’s in, what’s out - Endpoints Webinars - 9 month(s) ago
Endpoints News’ John Carroll and DealForma’s Chris Dokomajilar are back with our latest ranking of the top 100 VCs looking to make their mark in the biotech world. And we’re highlighting the occasion with a special webinar that will focus in on the field, which has been struggling with an
Source: webinars.endpts.comCategories: General Medicine News, General HCPsTweet-
Interested in biotech venture? Pencil in our annual special on the top 100 VCs in the business on the 21st, which kicks off with a webinar. Attendees will get it first. Great audience already on board. Should be an interesting convo. https://t.co/v9e24rgHaL
-
-
Mashup Score: 2The Endpoints 100 survey: What are industry execs saying about 2024? - Endpoints Webinars - 12 month(s) ago
Twice a year, I run the Endpoints 100 survey, checking in with 100+ industry execs — mostly CEOs — about the state of biotech today. There have been good times, bad times and the last 18 months, which have left more than a few bruises. Coinciding with our next Endpoints
Source: webinars.endpts.comCategories: General Medicine News, General HCPsTweet-
The Endpoints 100 survey is going out this morning. I'll be recruiting the panel this week and we'll have a roundtable CEO talk on December 6 -- you can sign up for free. There will be a Q&A with the audience. https://t.co/ljeAzUuol8
-
-
Mashup Score: 2The Endpoints 100 survey: What are industry execs saying about 2024? - Endpoints Webinars - 1 year(s) ago
Twice a year, I run the Endpoints 100 survey, checking in with 100+ industry execs — mostly CEOs — about the state of biotech today. There have been good times, bad times and the last 18 months, which have left more than a few bruises. Coinciding with our next Endpoints
Source: webinars.endpts.comCategories: General Medicine News, General HCPsTweet-
The Endpoints 100 survey is going out this morning. I'll be recruiting the panel this week and we'll have a roundtable CEO talk on December 6 -- you can sign up for free. There will be a Q&A with the audience. https://t.co/ljeAzUuol8
-
-
Mashup Score: 1Re-activating the immune system against cancer: The next I-O revolution - Endpoints Webinars - 1 year(s) ago
Patients dealing with cancers that have resisted immuno-oncology (IO) therapies potentially have a new treatment option on the horizon. More than a decade after the first checkpoint inhibitor raised hopes, next-generation investigational IO is lighting up clinics with long-sought encouraging results against the persistent “cold” tumors involved in colorectal, lung,
Source: webinars.endpts.comCategories: Hem/Oncs, Latest HeadlinesTweet-
21 minutes to go! Starting at 1 pm EST. Link to register and join the webinar @endpts. https://t.co/XtkoxJNPAw https://t.co/zbA9ot3iMN https://t.co/TztquyHp6R
-
-
Mashup Score: 9Re-activating the immune system against cancer: The next I-O revolution - Endpoints Webinars - 1 year(s) ago
Patients dealing with cancers that have resisted immuno-oncology (IO) therapies potentially have a new treatment option on the horizon. More than a decade after the first checkpoint inhibitor raised hopes, next-generation investigational IO is lighting up clinics with long-sought encouraging results against the persistent “cold” tumors involved in colorectal, lung,
Source: webinars.endpts.comCategories: Hem/Oncs, Latest HeadlinesTweet-
I’m so excited & honored. Still time to register for the webinar at @endpts today at 1 pm🕐EST. If there’s a class of drugs that I’m most excited about for my patients, it is #immunotherapy. Open to all: patients, caregivers, advocates, industry. Link: https://t.co/XtkoxJNPAw https://t.co/PHNYmJzYQO https://t.co/TztquyHp6R
-
-
Mashup Score: 0
Gene therapies have been exploding in popularity, with big and small players lining up scores of new programs looking to create entirely new standard of care models for a wide variety of diseases. But what does it take to de-risk a pivotal, registration-worthy gene therapy program? What are the pitfalls
Source: webinars.endpts.comCategories: Healthcare ProfessionalsTweet-
Finishing last details for our very timely webinar on gene therapy R&D at 2 pm ET, more than 1,000 registered for this so far. https://t.co/7x4AGVUrDA
-
Interested in biotech venture? Pencil in our annual special on the top 100 VCs in the business on the 21st, which kicks off with a webinar. Attendees will get it first. Great audience already on board. Should be an interesting convo. https://t.co/v9e24rgHaL